N-Nitrozodipropyloamina. Dokumentacja proponowanych wartości dopuszczalnych wielkości narażenia zawodowego

Szymańska, Jadwiga; Frydrych, Barbara; Bruchajzer, Elżbieta

doi:10.54215/ PiMOSP/3.118.2023

Artykuł - szczegóły

Tytuł artykułu

N-Nitrozodipropyloamina. Dokumentacja proponowanych wartości dopuszczalnych wielkości narażenia zawodowego

Autorzy

Szymańska Jadwiga , Frydrych Barbara , Bruchajzer Elżbieta

Wybrane pełne teksty z tego czasopisma

www.ciop.pl/pimosp_teksty

Identyfikatory

DOI

10.54215/ PiMOSP/3.118.2023

Warianty tytułu

N-Nitrosodipropylamine Documentation of proposed values of occupational exposure limits (OELs)

Języki publikacji

Abstrakty

N-Nitrozodipropyloamina (NDPA) jest jasnożółtą, klarowną cieczą, wrażliwą na światło. Jest to substancja chemiczna produkowana w małych ilościach do celów badawczych. Niewielkie ilości N-nitrozodipropyloaminy powstają jako produkt uboczny podczas procesów produkcyjnych (środki chwastobójcze, niektóre wyroby gumowe). W Polsce liczba narażonych na NDPA w 2019 r. wynosiła 149, a w 2020 r. 183 osoby, wśród których przeważały kobiety. N-Nitrozodipropyloamina jest substancją z listy priorytetowej ACSH (The Advisory Committee on Safety and Health at Work). Jest klasyfikowana jako substancja o małej lub umiarkowanej toksyczności ostrej. Informacje na temat toksyczności tego związku pochodzą głównie z wyników niewielkiej liczby badań na zwierzętach laboratoryjnych. Brak jest badań epidemiologicznych. W kilku badaniach dotyczących narażenia drogą pokarmową stwierdzono zmiany w przyroście masy ciała, uszkodzenie wątroby oraz zmiany nowotworowe. Działanie genotoksyczne NDPA obserwowano w badaniach zarówno w warunkach in vitro, jak i in vivo. NDPA jest klasyfikowana jako substancja rakotwórcza kategorii 1B, co oznacza, że ma potencjalne działanie rakotwórcze dla ludzi, przy czym klasyfikacja opiera się na badaniach przeprowadzonych na zwierzętach. EPA i IARC sklasyfikowały ten związek jako prawdopodobnie rakotwórczy dla ludzi (grupa 2B). Proponuje się przyjąć dla N-nitrozodipropyloaminy za wartość NDS stężenie 0,045 mg/m³ i oznakowanie „Carc. 1B”. Brak jest podstaw do ustalenia wartości chwilowej NDSCh oraz dopuszczalnej w materiale biologicznym DSB.

N-Nitrosodipropylamine (NDPA) is a pale yellow, clear liquid that is sensitive to light. It is a chemical produced in small quantities for research purposes. Small amounts of N-nitrosodipropylamine are arised as a by-product during production processes (herbicides, some rubber products). In Poland, the number of people exposed to NDPA in 2019 was 149 and in 2020 - 183 people, among whom women predominated. N-Nitrosodipropylamine is a substance on the ACSH (The Advisory Committee on Safety and Health at Work) priority list. It is classified as a substance of low to moderate acute toxicity. Information on the toxicity of this compound comes mainly from the results of a small number of laboratory animal studies. Epidemiological studies are lacking. A few studies on oral exposure have reported changes in body weight gain, liver damage and neoplastic changes. Genotoxic effects of NDPA have been observed in both in vitro and in vivo studies. NDPA is classified as a category 1B carcinogen, meaning that it has potential carcinogenic effects in humans, with classification based on animal studies. EPA and IARC have classified the compound as possibly carcinogenic to humans (Group 2B). It is proposed to adopt for N-nitrosodipropylamine a concentration of 0.045 mg/m³ as MAC value and to label “Carc. 1B”. There is no basis for setting an instantaneous value and the limit in biological material.

Słowa kluczowe

N-nitrozodipropyloamina NDPA toksyczność rakotwórczość narażenie zawodowe NDS

N-nitrosodipropylamine NDPA toxicity carcinogenicity occupational exposure MAC

Wydawca

Centralny Instytut Ochrony Pracy - Państwowy Instytut Badawczy

Czasopismo

Podstawy i Metody Oceny Środowiska Pracy

Rocznik

2023

Tom

Nr 4 (118)

Strony

51--77

Opis fizyczny

Bibliogr. 126 poz., tab.

Twórcy

autor

Szymańska Jadwiga

jadwiga.szymanska@umed.lodz.pl

Uniwersytet Medyczny w Łodzi Wydział Farmaceutyczny 90-151 Łódź, ul. J. Muszyńskiego 1 POLAND

https://orcid.org/0000-0002-3320-008X

autor

Frydrych Barbara

Uniwersytet Medyczny w Łodzi Wydział Farmaceutyczny 90-151 Łódź, ul. J. Muszyńskiego 1 POLAND

https://orcid.org/0000-0002-9383-5319

autor

Bruchajzer Elżbieta

Uniwersytet Medyczny w Łodzi Wydział Farmaceutyczny 90-151 Łódź, ul. J. Muszyńskiego 1 POLAND

https://orcid.org/0000-0002-4494-5722

Bibliografia

1. Adamson R.H., Sieber S.M. (1979). The use of nonhuman primates for chemical carcinogenesis studies. Ecotoxicol. Environ. Qual. 2, 275-302 [cyt. za: ATSDR 20]
2. Airoldi L., Macri A., Bonfanti M. i in. (1984). Kinetics and bioavailability of N-nitrosodiethanolamine after intravenous and cutaneous administration to rats. Fundam. Chem. Toxicol. 22, 133-138.
3. Althoff J., Grandjean C., Pour P. i in. (1977a). Comparison of the effect of ß-oxidized dipropylnitrosamine metabolites administered at equimolar doses to Syrian hamsters. Z. Krebsforsch. Klin. Onkol. Cancer Res. Clin. Oncol. 90, 141-148.
4. Althoff J., Pour P., Grandjean C. i in. (1977b). Transplacental effects of nitrosamines in Syrian hamsters: III. Dimethyl- and dipropylnitrosamine. Z. Krebsforsch. Klin. Onkol. Cancer Res. Clin. Oncol. 90, 79-86.
5. Althoff J., Grandjean C. (1979). In vivo studies with Syrian golden hamster: a transplacental bioassay of ten nitrosamines. Natl. Cancer Inst. Monogr. 51, 251-255 [cyt. za: ATSDR 2019].
6. Amacher D.E., Paillet S.C., Turner G.N. (1979). Utility of the mouse lymphoma L5178Y/TK assay for the detection of chemical mutagens. [W:] Banbury Report 2. Mammalian cel mutagenesis: the maturation of test systems. [Red.] A.W. Hsie i in. Cold Spring Harbor Laboratory. 277-293.
7. Amacher D.E., Paillet S.C. (1982). Hamster hepatocyte-mediated activation of procarcinogens to mutagens in the L5178Y/ TK mutation assay. Mutat. Res. 106, 305-316.
8. Amacher D.E., Paillet S.C. (1983). The activation of procarcinogens to mutagens by cultured rat hepatocytes in the L5178Y/ TK mutation assay. Mutat. Res. 113, 77-88.
9. Amlacher E., Rudolph C. (1981). The thymidine incorporation inhibiting screening system (TSS) to test carcinogenic substances: a nuclear DNA synthesis suppressive short-term test. Arch. Geschwulstforsch 51, 605-610.
10. Araki A., Muramatsu M., Matsushima T. (1984). Comparison of mutagenicities of N-nitrosamines on Salmonella typhimurium TA100 and Escherichia coli WP2 uvrA/pKM101 using rat and hamster liver S9. Gan 75, 8-16.
11. ATSDR, Agency for Toxic Substances and Disease Registry (2019). Toxicological profile for N-nitrosodi-N-propylamine. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service.
12. Bartsch H., Camus A., Malaveille C. (1976). Comparative mutagenicity of N-nitrosamines in a semi-solid and in a liquid incubation system in the presence of rat or human tissue fractions. Mutat. Res. 37, 149-162.
13. Bartsch H., Malaveille C., Camus A.M. i in. (1980). Validation and comparative studies on 180 chemicals with S. Typhimurium strains and V79 Chinese hamster cells in the presence of various metabolizing systems. Mutat. Res. 76, 1–50.
14. Bartsch H., Hietanen E., Malaveille C. (1989). Carcinogenic nitrosamines: free radical aspects of their action. Free Radic. Biol. Med. 7, 637-644.
15. Bauman P.A., Hotchkiss J.H., Parker R.S. (1985). Metabolism of N-nitrosodi-n-propylamine and N-nitrosodiallylamine by isolated rat hepatocytes. Cancer Lett. 28, 229-236.
16. Blattmann L., Preussmann R. (1973). [Structure of rat urinary metabolites of carcinogenic dialkylnitrosamines]. Z. Krebsforsch. Klin. Onkol. 79, 3-5.
17. Bradley M.O., Dysart G. (1981). Measurements on DNA single and double strand breaks and their repair by filter elution in rat hepatocytes nitrosamines and gamma irradiation. Health Environ. Res. Online (HERO) 3, 27–30.
18. Bradley M.O., Dysart G., Fitzsimmons K. i in. (1982). Measurements by filter elution of DNA single- and doublestrand breaks in rat hepatocytes: effects of nitrosamines and gamma-irradiation. Cancer Res. 42(7), 2592-2597.
19. Brambilla G., Cavanna M., Pino A. i in. (1981). Quantitative correlation among DNA damaging potency of six N-nitroso compounds and their potency in inducing tumor growth and bacterial mutations. Carcinogenesis 2, 425-429.
20. Brambilla G., Carlo P., Finollo R. i in. (1987a). Dose-response curves for liver DNA fragmentation-induced in rats by sixteen N-nitroso compounds as measured by viscometric and alkaline elution analyses. Cancer Res. 47, 3485-3491.
21. Brambilla G., Martelli A., Robbianao L. i in. (1987b). Induction of DNA fragmentation and repair in human hepatocytees by N-nitroso compounds. Proc. AACR 28, 114 [cyt. za: ATSDR 2019].
22. Brittebo E.B., Tjälve H. (1982). Tissue-specificity of N-nitrosodibutylamine metabolism in Sprague-Dawley rats. Chem. Biol. Interact. 38, 231-242.
23. Bronaugh R.L., Congdon E.R., Scheuplein R.J. (1979). The percutaneous absorption of N-nitrosodiethanolamine through excised human skin. J. Invest. Dermatol. 72, 204.
24. Bronaugh R.L., Congdon E.R., Scheuplein R.J. (1981). The effect of cosmetic vehicles on the penetration of N-nitrosodiethanolamine through excised human skin. J. Invest. Dermatol. 76, 94-96.
25. Bruchajzer E., Frydrych B., Szymańska J. (2019). N-Nitrozodimetyloamina. Dokumentacja proponowanych dopuszczalnych wielkości narażenia zawodowego. Podst. Met. Oceny Srodow. Pr. 3(101), 65-119.
26. ChemIDplus (2022). N-Nitrosodi-n-propylamine.
27. Dahl A.R. (1985). Mutagenicity of some dialkylnitrosamines, cyclic nitrosamines and N,N-diethanolnitrosamine in Salmonella typhimurium with rat and rabbit nasal, lung and liver S9 homogenates. Mutat. Res. 158, 141-147.
28. Daugherty J.P., Klapp N.K. (1976). Studies on nitrosamine metabolism: I. Subcellular distribution of radioactivity in tumor-susceptible tissues of RFM mice following administration of [14C]dimethylnitrosamine. Life Sci. 19, 265-271.
29. DFG, Deutsche Forschungsgemeinschaft (1991). Occupational Toxicants. N-Nitrosamines. Critical Data Evaluation of MAK. Values and classification of carcinogenes. VCH Verlagsgesellschaft, mbh, Weinheim, FRG, 1, 261-289.
30. DFG, Deutsche Forschungsgemeinschaft (2020). MAK- und BAT-Werte-Liste 2020. Mitteilung 56.
31. DFG, Deutsche Forschungsgemeinschaft (2022). MAK- und BAT-Werte-Liste 2022.
32. Diaz Gomez M.I., Swann P.F., Magee P.N. (1977). The absorption and metabolism in rats of small oral doses of dimethylnitrosamine. Implication for the possible hazard of diemthylnitrosamine in human food. Biochem. J. 164, 497-500.
33. Dickhaus S., Reznik G., Green U. i in. (1977). The carcinogenic effect of beta-oxidized dipropylnitrosamine in mice: I. Dipropylnitrosamine and methyl-propylnitrosamine. Z. Krebsforsch. Klin. Onkol. 90, 253-258.
34. Druckrey H., Preussmann R., Ivankovic S. i in. (1967). Organotrope carcinogene Wirkungen bei 65 verschiedenen N-Nitroso-Verbindungen an BD-Ratten. Z. Krebsforsch. 69, 103-201.
35. Edwards G.S., Peng M., Fine D.H. i in. (1979). Detection of N-nitrosodiethanolamine in human urine following application of a contaminant cosmetic. Toxicol. Lett. 4, 217-222.
36. EMA, European Medicines Agency (2020). Committee for Medicinal Products for Human Use (CHMP). Assessment report. Procedure under Article 5(3) of Regulation EC (No) 726/2004. Nitrosamine impurities in human medicinal products. EMA/369136/2020.
37. Farrelly J.G., Stewart M.L., Lijinsky W. (1984). The metabolism of nitrosodi-n-propylamine, nitrosodiallylamine and nitrosodiethanolamine. Carcinogenesis 5, 1015-101
38. Foiles P.G., Miglietta L.M., Akerkar S.A. i in. (1988). Detection of 0-6-methyldeoxyguanosine in human placental DNA. Cancer Res. 48, 4184–4188.
39. Griciute L., Castegnaro M., Bereziat J.C. (1982). Influence of ethyl alcohol on the carcinogenic activity of N-nitrosodi-n-propylamine. IARC Sci. Publ. 41, 643–648 [cyt. za: ATSDR 2019].
40. Guttenplan J.B. (1987). Structure-activity relationships in metabolism and mutagenicities of N-nitrosamines. IARC Sci. Publ. 84, 129-131.
41. Guttenplan J.B., Hu Y.C. (1984). Mutagenesis by N-nitroso compounds in Salmonella typhimurium TA102 and TA104: evidence for premutagenic adenine or thymine DNA adducts. Mutat. Res. 141, 153-159.
42. Hamada S., Ohyama W., Takashima R. i in. (2015). Evaluation of the repeated-dose liver and gastrointestinal tract micronucleus assays with 22 chemicals using young adult rats: summary of the collaborative study by the Collaborative Study Group for the Micronucleus Test (CSGMT)/The Japanese Environmental Mutagen Society (JEMS) - Mammalian Mutagenicity Study Group (MMS). Mutat. Res. Genet. Toxicol. Environ. Mutagen. 780-781, 2-17.
43. HSDB, Hazardous Substances Data Bank (2009). Komputerowa baza danych.
44. HSDB, Hazardous Substances Data Bank (2019). Komputerowa baza danych.
45. IARC, International Agency for Research on Cancer (1978). Monographs on the evaluation of the carcinogenic risk of chemicals to humans: some N-nitroso compounds. Geneva: WHO, IARC. 17, 177-189.
46. IARC, International Agency for Research on Cancer (1987). Monographs on the evaluation of the carcinogenic risk of chemicals to humans. Overall evaluations of carcinogenicity: an updating of IARC Monographs vol. 1-42. Geneva: WHO, IARC, Suppl. 7, 68.
47. IARC, International Agency for Research on Cancer (2022). Monographs of the identification of carcinogenic hazards to humans. Agents classified by the IARC Monographs, vol. 1-131. Last updated: 8.04.2022.
48. IFA, Institute for Occupational Safety and Health of the German Social Accident Insurance (2022a). GESTIS Chemical Substance Database. N-nitrosodipropylamine.
49. IFA, Institute for Occupational Safety and Health of the German Social Accident Insurance (2022b). GESTIS Internatal Limit Values. N-Nitrosodi-n-propylamine. https://limitvalue.ifa.dguv.de/WebForm_ueliste2.aspx [dostęp: 22.06.2022].
50. IMP, Instytut Medycyny Pracy (2021). Centralny Rejestr Danych o Narażeniu na Substancje, Czynniki i Procesy Technologiczne o Działaniu Rakotwórczym lub Mutagennym w Środowisku Pracy.
51. IRIS, Integrated Risk Information System (2002). Chemical Assessment Summary. N-Nitrosodi-n-propylamine; CASRN 621-64-7.
52. Ishinishi N., Tanaka A., Hisanaga A. i in. (1988). Comparative study on the carcinogenicity of N-nitrosodiethylamine, N-nitrosodimethylamine, N-nitrosomorpholine, N-nitrosopyrrolidine and Nnitrodi-n-propylamine to the lung of Syrian golden hamsters following intermittent instillations to the trachea. Carcinogenesis 9, 947-950.
53. Jones C.A., Huberman E. (1980). A sensitive hepatocyte-mediated assay for the metabolism of nitrosamines to mutagens for mammalian cells. Cancer Res. 40, 406-411.
54. Kaminski N.E., Jordan S.D., Page D. i in. (1989). Suppression of humoral immune responses by dialkylnitrosamines: structure-activity relationships. Fundam. Appl. Toxicol. 12, 321-332.
55. Kaneko A., Hayashi M., Yoshikawa K. i in. (1978). Chromosome aberration tests combined with S-9 metabolic activation system in vitro. Mutat. Res. 54, 240 [cyt. za: ATSDR 2019].
56. Kirkland D., Aardema M., Henderson L. i in. (2005). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens: I. Sensitivity, specificity and relative predictivity. Mutat. Res. 584(1-2), 1-256.
57. Klein R.G., Schmezer P. (1984). Quantitative measurement of the exhalation rate of volatile N-nitrosamines in inhalation experiments with anesthetized Sprague-Dawley rats. IARC Sci. Publ. 57, 513–517
58. Knasmuller S., Szakmary A., Kehrer M. (1990). Use of differential DNA-repair host mediated assays to investigate the biotransformation of xenobiotics in Drosophila melanogaster: 1. Genotoxic effects of nitrosamines. Chem. Biol. Interact. 75, 17-29.
59. Knasmüller S., Parzefall W., Sanyal R. i in. (1998). Use of metabolically competent human hepatoma cells for the detection of mutagens and antimutagens. Mutat. Res. 402(1-2), 185-202.
60. Koehl W., Eisenbrands G. (1999). N-Nitroso compounds. [W:] Toxicology. [Red.] H. Marquardt, S.G. Schäfer, R. McClellan i in. Chapter 31. San Diego: Academic Press, 743–775.
61. Krüger F.W. (1971). Metabolism of nitrosamines in vivo: I. Evidence for beta-oxidation of aliphatic di-n-alkylnitrosamines: the simultaneous formation of 7-methylguanine and 7-propyl- or 7-butylguanine after application of di-n-propylor di-n-butylnitrosamine. Z. Krebsforsch. Klin. Onkol. 76, 145–154 [cyt. za: ATSDR 2019].
62. Krüger F.W., Bertram B. (1973). Metabolism of nitrosamines in vivo: III. On the methylation of nucleic acids by aliphatic di-n-alkylnitrosamines in vivo resulting from beta-oxidation: the formation of 7-methylguanine after application of 2-oxopropylpropyl-nitrosamine and methylpropylnitrosamine. Z. Krebsforsch. Klin. Onkol. 80, 189-196 [cyt. za: ATSDR 2019]
63. Kuroki T., Drevon C., Montesano R. (1977). Microsome-mediated mutagenesis in V79 Chinese hamster cells by various nitrosamines. Cancer Res. 37, 1044–1050.
64. Langenbach R. (1986). Mutagenic activity and structure-activity relationship of short-chain dialkyl N-nitrosamines in a hamster hepatocyte V79 cell-mediated system. Mutat. Res. 163, 303–311.
65. Lethco E.J., Wallace W.C., Brouwer E. (1982). The fate of N-nitrosodiethanolamine after oral and topical administration to rats. Food Chem. Toxicol. 20, 401-406.
66. Leung K.H., Archer M.C. (1981). Urinary metabolites of N-nitrosodipropylamine, N-nitroso-2-hydroxypropylpropylamine and N-nitroso-2-oxopropylpropylamine in the rat. Carcinogenesis 2(9), 859-862.
67. Leung K.H., Archer M. (1984). Studies on the metabolic activation of beta-keto nitrosamines: mechanisms of DNA methylation by N-(2-oxopropyl)-N-nitrosourea and N-nitroso-n-acetoxymethyl-N-2-oxopropylamine. Chem. Biol. Interact. 48, 169–179 [cyt. za: ATSDR 2019]
68. Lijinsky W., Taylor H.W. (1978). Comparative carcinogenicity of some derivatives of nitrosodi-n-propylamine in rats. Exotoxicol. Environ. Saf. 2, 421–426.
69. Lijinsky W., Taylor H.W. (1979). Carcinogenicity of methylated derivatives of N-nitrosodiethylamine and related compounds in Sprague-Dawley rats. J. Natl. Cancer Inst. 62, 407–4
70. Lijinsky W., Losikoff A.M., Sansone E.P. (1981). Penetration of rat skin by N-nitrosodiethanolamine and N-nitrosomorpholine. J. Natl. Cancer Inst. 66, 125-128.
71. Lijinsky W., Reuber M.D. (1981). Comparative carcinogenesis of some aliphatic nitrosamines in Fischer rats. Cancer Lett. 14, 297-302
72. Martelli A., Robbiano L., Gazzaniga G.M. i in. (1988). Comparative study of DNA damage and repair induced by ten N-nitroso compounds in primary cultures of human and rat hepatocytes. Cancer Res. 48, 4144-4152.
73. Martin C.N., McDermid A.C., Garner R.C. (1978). Testing of known carcinogens and noncarcinogens for their ability to induce unscheduled DNA synthesis in HeLa cells. Cancer Res. 38, 2621-2627.
74. Marzulli F.N., Anjo D.M., Maibach H.I. (1981). In vivo skin penetration studies of 2,4-toluenediamine, 2,4diaminoanisole, 2-nitro-p-phenylenediamine, p-dioxane and N-nitrosodiethanolamine in cosmetics. Food Cosmet. Toxicol. 19, 743-747.
75. Matsuoka A., Hayashi M., Ishidate M. (1979). Chromosomal aberration tests on 29 chemicals combined with S9 mix in vitro. Mutat. Res. 66, 277-290.
76. McMahon R.E., Cline J.C., Thompson C.Z. (1979). Assay of 855 test chemicals in ten tester strains using a new modification of the Ames test for bacterial mutagens. Cancer Res. 39, 682-693.
77. Mersch-Sundermann V., Schneider U., Klopman G. i in. (1994). SOS induction in Escherichia coli and Salmonella mutagenicity: a comparison using 330 compounds. Mutagenesis 9, 205–224.
78. Moore C.M., Goodall C.M., Beagley K.W. i in. (1985). Mutagenic activation of dialkylnitrosamines by intact urothelial cells. Mutat. Res. 157, 95-105.
79. Mori Y., Yamazaki H., Toyoshi K. i in. (1985a). Inhibitory effect of organic solvents on the mutagenicity of N-nitrosodialkylamines in Salmonella. Mutat. Res. 142, 153-158.
80. Mori Y., Yamazaki H., Toyoshi K., Makino T., Obara T., Yokose Y., Konishi Y. (1985b). Mutagenic activation of carcinogenic N-nitrosopropylamines by rat liver: evidence for a cytochrome P-450 dependent reaction. Carcinogenesis 6, 415-420.
81. Morita T., Asano N., Awogi T. i in. (1997). Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens (groups 1, 2A and 2B) the summary report of the 6th collaborative study by CSGMT/JEMS MMS: Collaborative Study of the Micronucleus Group Test: Mammalian Mutagenicity Study Group. Mutat. Res. 389, 3-122.
82. Nakajima T., Tanaka A., Tojyo K. (1974). The effect of metabolic activation with rat liver preparations on the mutagenicity of several N-nitrosamines on a streptomycin-dependent strain of Escherichia coli. Mutat. Res. 26, 361-366.
83. NIOSH, National Institute for Occupational Safety and Health (1982). Health hazard evaluation. Report no. HETA 82-156- 1231. Seller-Globe Corporation, Keokuk, IA. PB84172915 [cyt. za: ATSDR 2019].
84. Nishie K., Norred W.P., Wasserman A. i in. (1972). Phototoxicity and differential hepatotoxicity as biological indicators of nitrosamine activity. Toxicol. Appl. Pharmacol. 23, 680-691.
85. Nowak A., Libudzisz Z. (2008). Karcynogeny w przewodzie pokarmowym człowieka. Żywność 4(59), 9–25.
86. OEHHA, California Office of Environmental Health Hazard Assessment (2009). N-Nitrosodi-n-propylamine.
87. Okochi E., Kurahashi A., Mochizuki M. (1997). Detection of mutagenicity in Ames test using a metalloporphyrin/oxidant model system for cytochrome P450. Mutat. Res. 373, 99-105.
88. Park K.K., Wishnok J.S., Archer M.C. (1977). Mechanism of alkylation by N-nitroso compounds: detection of rearranged alcohol in the microsomal metabolism of N-nitrosodi-n-propylamine and base-catalyzed decomposition of N-n-propyl-N-nitrosourea. Chem. Biol. Interact. 18, 349-354.
89. Park K.K., Archer M.C. (1978). Microsomal metabolism of N-nitrosodi-n-propylamine: formation of products resulting from alpha- and beta-oxidation. Chem. Biol. Interact. 22, 83-90.
90. Park K.K., Archer M.C., Wishnok J.S. (1980). Alkylation of nucleic acids by N-nitrosodi-n-propylamine: evidence that carbonium ions are not significantly involved. Chem. Biol. Interact. 29, 139-144.
91. Parodi S., Taningher M., Santi L. (1982). Alkaline elution in vivo: fluorometric analysis in rats. Quantitative predictivity of carcinogenicity, as compared with other short-term tests. [W:] Indicators of genotoxic exposure. Banbury Report 13, 137-155 [cyt. za: Toxicol. profile 2019].
92. Parodi S., Zunino A., Ottaggio L. i in. (1983). Quantitative correlation between carcinogenicity and sister chromatid exchange induction in vivo for a group of 11 N-nitroso derivatives. J. Toxicol. Environ. Health 11, 337–346.
93. Pedal I., Besserer K., Goerttler K. i in. (1982). Fatal nitrosamine poisoning. Arch. Toxicol. 50, 101
94. Phillipson C.E., Ioannides C. (1985). Metabolic activation of nitrosamines to mutagens by various animal species including man. Biochem. Pharmacol. 34, 441-442.
95. Pour P., Krüger F.W., Cardesa A. i in. (1973). Carcinogenic effect of di-n-propylnitrosamine in Syrian golden hamster. J. Natl. Cancer Inst. 51, 1019-1027.
96. Preussmann R., Würtele G., Eisenbrand G. i in. (1978). Urinary excretion of N-nitrosodiethanolamine administered orally to rats. Cancer Lett. 4, 207-209.
97. Preussmann R., Spiegelhalder B., Eisenbrand G. i in. (1981). Urinary excretion of Nnitrosodiethanolamine in rats following its epicutaneous and intratracheal administration and its formation in vivo following skin application of diethanolamine. Cancer Lett. 13, 227-231.
98. Probst G.S., McMahon R.E., Hill L.E. i in. (1981). Chemically-induced unscheduled DNA synthesis in primary rat hepatocyte cultures: a comparison with bacterial mutagenicity using 218 compounds. Environ. Mutagen. 3, 11-32.
99. PubChem (2022). N-Nitrosodi-n-propylamine.
100. Rao T.K., Young J.A., Lijinsky W. i in. (1979). Mutagenicity of aliphatic nitrosamines in Salmonella typhimurium. Mutat. Res. 66, 1-7.
101. Rao T.K., Allen B.E., Winton W. i in. (1981). Nitrosamine-induced mutagenesis in Escherichia coli K12 (343/113): I. Mutagenic properties of certain aliphatic nitrosamines. Mutat. Res. 89, 209-215.
102. Rao T.K., Epler J.L., Lijinsky W. (1982). Structure activity studies with N-nitrosamines using Salmonella typhimurium and Escherichia coli. IARC Sci. Publ. 41, 543-551
103. Reznik G., Mohr U., Krüger F.W. (1975). Carcinogenic effects of di-n-propylnitrosamine, β-hydroxypropyl-n-propylnitrosamine, and methyl-n-propylnitrosamine on Sprague-Dawley rats. J. Natl. Cancer Inst. 54, 937–943 [cyt. za: DFG 1991; IARC 1978].
104. Robbiano L., Mereto E., Corbu C. i in. (1996). DNA damage induced by seven N-nitroso compounds in primary cultures of human and rat kidney cells. Mutat. Res. 368, 41-47.
105. RoC (2002). 10th Report on Carcinogens. N-Nitrosodi-n-propylamine.
106. RoC (2021). 15th Report on Carcinogens. N-Nitrosodi-n-propylamine.
107. Rozporządzenie Parlamentu Europejskiego i Rady (WE) nr 1272/2008 z dnia 16 grudnia 2008 r. w sprawie klasyfikacji, oznakowania i pakowania substancji i mieszanin, zmieniające i uchylające dyrektywy 67/548/EWG i 1999/45/WE oraz zmieniające rozporządzenie (WE) nr 1907/2006. Dz. Urz. UE L 353 z 31.12.2008 r.
108. Sax’s dangerous properties of industrial materials (2004). 11th Edition. [Red.] R.J. Lewis Sr. Wiley-Interscience, Wiley & Sons, Hoboken, NJ, p. 2710.
109. Sedlo I., Kolonić T., Tomić S. (2021). Presence of nitrosamine impurities in medicinal products. Arh. Hig. Rada Toksikol. 72, 1-5.
110. Shank R.C. (1975). Toxicology of N-nitroso compounds. Toxicol. Appl. Pharmacol. 31, 361-368.
111. Shu L., Hollenberg P.F. (1996). Identification of the cytochrome P450 isozymes involved in the metabolism of N-nitrosodipropyl-, N-nitrosodibutyl- and N-nitroso-n-butyl-n-propylamine. Carcinogenesis 17, 839–848.
112. Skowroń J., Czerczak S. (2013). Zasady ustalania dopuszczalnych poziomów narażenia dla czynników rakotwórczych w środowisku pracy w Polsce i w krajach Unii Europejskiej. Med. Pr. 64, 541-563.
113. Supelco (2021). N-Nitrosodi-n-propylamine. Karta charakterystyki
114. Suzuki E., Okada M. (1981). Metabolic fate of N,N-dipropylnitrosamine and N,N-diamylnitrosamine in the rat, in relation to their lack of carcinogenic effect on the urinary bladder. Gan 72, 552–561.
115. Suzuki T., Itoh S., Nakajima M. i in. (1999). Target organ and time-course in the mutagenicity of five carcinogens in MutaMouse: a summary report of the second collaborative study of the transgenic mouse mutation assay by JEMS/MMS. Mutat. Res. 444, 259-268.
116. Takayama S., Thorgeirsson U.P., Adamson R.H. (2008). Chemical carcinogenesis studies in nonhuman primates. Proc. Jpn. Acad. Ser. B 84, 176-188.
117. Teiber J.F., Hollenberg P.F. (2000). Identification of the human liver microsomal cytochrome P450s involved in the metabolism of N-nitrosodi-n-propylamine. Carcinogenesis 21, 1559-1566.
118. Teiber J.F., Macé K., Hollenberg P.F. (2001). Metabolism of the β-oxidized intermediates of N-nitrosodi-n-propylamine: N-nitroso-β-hydroxypropylpropylamine and N-nitroso-β-oxopropylpropylamine. Carcinogenesis 22, 499–506
119. Terashima Y., Yokoi R., Takakura I. i in. (2015). Detection of micronuclei in hepatocytes isolated from young adult rats repeatedly treated with N-nitrosodi-n-propylamine. Mutat. Res. 780-781, 36-40.
120. Thorgeirsson U.P., Dalgard D.W., Reeves J. i in. (1994). Tumor incidence in a chemical carcinogenesis study of nonhuman primates. Regul. Toxicol. Pharmacol. 19, 130-151.
121. Thresher A., Foster R., Ponting D.J. i in. (2020). Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data. Regul. Toxicol. Pharmacol. 116, 104749
122. TRGS 552 (2018). Technische Regein für Gefahrstoffe. Krebserzeugende N-Nitrosamine der Kat 1A and 1B
123. US EPA, U.S. Environmental Protection Agency (1986). Health and environmental effects profile for nitrosamines. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH for the Office of Solid Waste and Emergency Response, Washington, DC.
124. Wishnok J.S., Snow K., Woolworth V. (1982). Passage of nitrosamines through animal membranes. IARC Sci. Publ. 41, 435–442.
125. Yahagi T., Nagao M., Seino Y. i. in. (1977). Mutagenicities of N-nitrosamines on Salmonella. Mutat. Res. 48, 121–129.
126. Yamazaki H., Mori Y., Toyoshi K. i in. (1985). Genotoxicity of carcinogenic N-nitrosopropylamine derivatives in the hepatocyte primary culture/DNA repair test. Mutat. Res. 144, 197-202.

Uwagi

Opracowanie rekordu ze środków MNiSW, umowa nr SONP/SP/546092/2022 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2024).

Typ dokumentu

Bibliografia

Identyfikator YADDA

bwmeta1.element.baztech-ac6db996-a781-4091-b4da-c62c84a9fed0